Ambroxol-ALSI, tablets 30 mg 30 pcs

Mucolytic agent, stimulates prenatal lung development (increases the synthesis, secretion of surfactant and blocks its breakdown).

• Has secretomotor, secretolytic and expectorant action;

• Stimulates serous gland cells of the mucous membrane of the bronchi, increases the content of mucous secretion and the release of surfactant (surfactant) in the alveoli and bronchi;

• Normalizes the disturbed ratio of serous and mucous components of sputum.

By activating hydrolyzing enzymes and increasing the release of lysosomes from Clark cells, reduces sputum viscosity. Increases motor activity of the atrial epithelium and increases mucociliary transport.

After oral administration the action comes within 30 minutes and lasts for 612 hours.

Indications

Diseases of the respiratory tract with the formation of viscous sputum: acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease (COPD), bronchial asthma with difficulty in sputum discharge, bronchiectasis, cystic fibrosis.

Pharmacological effect

A mucolytic agent that stimulates the prenatal development of the lungs (increases the synthesis and secretion of surfactant and blocks its breakdown).

It has secretomotor, secretolytic and expectorant effects;

Stimulates serous cells of the glands of the bronchial mucosa, increases the content of mucous secretion and the release of surfactant in the alveoli and bronchi;

Normalizes the disturbed ratio of serous and mucous components of sputum.

By activating hydrolyzing enzymes and enhancing the release of lysosomes from Clark cells, it reduces the viscosity of sputum. Increases the motor activity of the ciliated epithelium, increases mucociliary transport.

After oral administration, the effect occurs within 30 minutes and lasts for 6-12 hours.

Special instructions

It should not be combined with antitussive drugs that impede the removal of sputum.

Active ingredient

Ambroxol

Composition

One tablet contains:

Active substance:

Ambroxol hydrochloride – 30 mg.

Excipients:

Lactose monohydrate (milk sugar) – 171.0 mg;

Potato starch – 36.0 mg;

Colloidal silicon dioxide (aerosil) – 1.8 mg;

Magnesium stearate – 1.2 mg.

Contraindications

Hypersensitivity, children under 6 years of age, pregnancy (1st trimester).

With caution: The drug should be used with caution in patients with gastric and duodenal ulcers, as well as in patients with renal and liver failure.

Use during pregnancy and lactation:

The drug is not recommended for use during the first trimester of pregnancy. If it is necessary to use ambroxol in the II-III trimesters of pregnancy and during breastfeeding, the potential benefit to the mother should be assessed against the possible risk to the fetus/child.

Interaction

Combined use with antitussive drugs leads to difficulty in sputum discharge while reducing cough.

Increases the penetration of amoxicillin, cefuroxime, erythromycin and doxycycline into the bronchial secretions.

Overdose

Symptoms: nausea, vomiting, diarrhea.

Treatment: artificial vomiting, gastric lavage in the first 1-2 hours after taking the drug; intake of fat-containing foods.

Recommendations for use

Inside, during meals, with a small amount of liquid. Adults and children over 12 years of age are prescribed 30 mg 3 times a day in the first 2-3 days, then 30 mg 2 times a day or 15 mg (half a tablet) 3 times a day, children 6-12 years old – 15 mg (half a tablet) 2-3 times a day.

It is not recommended to use without medical prescription for more than 4-5 days.

Side effect

Allergic reactions: skin rash, urticaria, angioedema, in some cases – allergic contact dermatitis, anaphylactic shock.

Rarely – weakness, headache, diarrhea, dry mouth and respiratory tract, exanthema, rhinorrhea, constipation, dysuria. With long-term use in high doses – gastralgia, nausea, vomiting.

Functional features

Absorption is high, time to reach maximum concentration in the blood (TCmax) is 2 hours, binding to plasma proteins is 80%. Penetrates the blood-brain barrier, placental barrier, and is excreted in breast milk.

Metabolism – in the liver, forms dibromoantranilic acid and glucuronic conjugates. The half-life (T1/2) is 7‑12 hours. Excreted by the kidneys: 90% in the form of water-soluble metabolites, unchanged – 5%. T1/2 increases with severe chronic renal failure, does not change with impaired liver function.

Storage conditions

In a dry place, protected from light and out of reach of children, at a temperature not exceeding 25°C.

Shelf life

3 years. Do not use after the date indicated on the package.

Manufacturer

ALSI Pharma, Russia